US pharmaceutical company Par Health Inc announced on Friday the launch of its generic version of Merck's Janumet XR (sitagliptin and metformin HCl extended-release) tablets for oral use, following final approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application.

Par Health's sitagliptin metformin XR is the first and currently the only FDA-approved generic of Janumet XR available in the United States. According to IQVIA data, Janumet XR had estimated annual US sales of approximately USD269.9m for the 12 months ended May 2026.

Janumet XR is a registered trademark of Merck Sharp & Dohme LLC.